GENE ONLINE|News &
Opinion
Blog

2025-11-27|

Tetrapeptide From Microbial Coculture Found to Target Harmful Algal Species Alexandrium fundyense

by GOAI
Share To

Researchers have identified a tetrapeptide produced by microbial coculture that demonstrates a unique algicidal mechanism against the harmful algal species Alexandrium fundyense. The study, published on November 27, 2025, highlights the potential of this tetrapeptide in targeting and mitigating the effects of harmful algal blooms caused by A. fundyense, which is known for producing toxins that can impact marine ecosystems and human health.

The research team observed that the tetrapeptide exhibited selective algicidal activity against A. fundyense without affecting other non-target organisms in the environment. The study detailed how microbial cocultures were utilized to produce the compound, which was then tested for its effectiveness in inhibiting or killing A. fundyense cells. Researchers further analyzed its mechanism of action, noting that it operates differently from previously known algicidal agents. This discovery adds to ongoing efforts to understand and manage harmful algal blooms through targeted biological approaches.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top